Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 8, 2008

GSK Licenses BioWa’s Potelligent Technology

  • BioWa licensed its Potelligent technology to GlaxoSmithKline for use in developing and commercializing select GSK antibodies with enhancement of antibody-dependent cellular cytotoxicity (ADCC).

    BioWa will provide GSK with non- exclusive commercial rights to use the technology for multiple antibodies. In return, BioWa will receive technology access fees, and may receive milestone payments and royalties from resulting products which are developed by GSK.

    According to BioWa, Potelligent improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics.

  • You’re all set! Thank you for subscribing to GEN Highlights.